Neuroblastoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The neuroblastoma market reached a value of USD 261.8 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 339.8 Million by 2035, exhibiting a growth rate (CAGR) of 2.41% during 2025-2035.

The neuroblastoma market has been comprehensively analyzed in IMARC's new report titled "Neuroblastoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Neuroblastoma refers to a type of cancer that develops in the immature nerve cells (neuroblasts) of the sympathetic nervous system. It usually starts in the adrenal glands, which are located above the kidneys but can also develop in other parts of the body, such as the neck, chest, abdomen, pelvis, etc. The disease generally affects infants and young children, although it can occur in adults as well. Some common symptoms are a lump in the abdomen, which may result in abdominal pain or swelling and lead to constipation or difficulty urinating. Various other indications may include bone pain, breathing problems, unexplained weight loss, fatigue, etc. In some cases, neuroblastoma may also cause fever, high blood pressure, or rapid heartbeat. The diagnosis of the ailment usually begins with a physical exam and a review of the patient's medical history. Several investigations may be used to confirm the prognosis, including imaging studies such as X-rays, ultrasounds, CT scans, MRI scans, etc., which can aid in identifying the size and location of the tumor. Additionally, numerous blood and urine tests may also be utilized to check for certain substances that are often elevated in patients with neuroblastoma. A biopsy is also performed to help confirm the diagnosis.

The increasing prevalence of genetic mutations that affect the development of nerve cells and the rising cases of chromosomal abnormalities, such as changes in the number or structure of chromosomes, are primarily driving the neuroblastoma market. In addition to this, the emerging popularity of proton therapy, since it is less damaging to the surrounding healthy tissues than traditional radiation therapy and helps treat neuroblastoma located near vital organs, is acting as another significant growth-inducing factor. Furthermore, the inflating application of gene expression profiling (GEP) to help identify the genetic signature of neuroblastoma and predict the prognosis and response to treatment is creating a positive outlook for the market. Moreover, several key players are making extensive investments in R&D activities to introduce targeted therapies that attack cancer cells while leaving healthy cells untouched, thereby improving clinical outcomes and reducing side effects. This, in turn, is also propelling the market growth. Additionally, the escalating demand for combination therapies which offer greater efficacy than single therapies alone and lower the risk of resistance developing to a single treatment is expected to drive the neuroblastoma market in the coming years.   

IMARC Group's new report provides an exhaustive analysis of the neuroblastoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for neuroblastoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuroblastoma market in any manner.

Recent Developments:

• In August 2025, SERB Pharmaceuticals and Y-mAbs Therapeutics announced that they had entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA (naxitamab-gqgk), in an all-cash transaction, representing an equity value for Y-mAbs of approximately $412 million.

Key Highlights:

• Neuroblastoma affects 10.2 children per million under the age of 15, with almost 500 new cases diagnosed each year.
• Neuroblastomas are diagnosed in around nine out of ten children by the age of five.
• Neuroblastoma is more common in white people and somewhat more prevalent in males than in girls (male-to-female ratio of 1.3:1).
• Neuroblastoma causes roughly 15% of all cancer-related fatalities in the pediatric population.
• Every year, approximately 700 to 800 new cases of neuroblastoma are diagnosed in the United States.

Drugs:

Unituxin (dinutuximab) is a monoclonal chimeric antibody made up of murine variable heavy and light chain regions, as well as a human constant region for heavy chain kappa. Unituxin reacts selectively with the ganglioside GD2, which is extensively expressed on the surface of neuroblastoma cells and minimally expressed on normal human neurons, peripheral pain fibers, or skin melanocytes.

67Cu-SARTATE by Clarity Pharmaceuticals is a targeted radiopharmaceutical that binds to somatostatin receptor 2 (SSTR2), which is overexpressed on neuroblastoma cells. The peptide component enables selective tumor targeting, while the copper-67 radionuclide emits beta particles, delivering cytotoxic radiation directly to cancer cells. This combination induces DNA damage and cell death while sparing most normal tissues.

Racotumomab (1E10 Mab, anti-idiotype cancer vaccine; Vaxira) is being developed for the treatment of neuroblastoma. The medication candidate is delivered by the intradermal method. Racotumomab is a murine monoclonal antibody that induces a particular immune response to glycolylated gangliosides (NeuGcGM3) seen in tumor cells.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the neuroblastoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the neuroblastoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current neuroblastoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the neuroblastoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the neuroblastoma across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the neuroblastoma across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of neuroblastoma across the seven major markets?
• What is the number of incident cases (2019-2035) of neuroblastoma by age across the seven major markets?
• What is the number of incident cases (2019-2035) of neuroblastoma by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of neuroblastoma by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with neuroblastoma across the seven major markets?
• What is the size of the neuroblastoma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend neuroblastoma of?
• What will be the growth rate of patients across the seven major markets?

Neuroblastoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for neuroblastoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuroblastoma market?
• What are the key regulatory events related to the neuroblastoma market?
• What is the structure of clinical trial landscape by status related to the neuroblastoma market?
• What is the structure of clinical trial landscape by phase related to the neuroblastoma market?
• What is the structure of clinical trial landscape by route of administration related to the neuroblastoma market?